Navigation Links
'Superdrug' Against Range of Viruses Shows Promise in Animal Trials
Date:8/11/2011

By Steven Reinberg
HealthDay Reporter

THURSDAY, Aug. 11 (HealthDay News) -- A potentially groundbreaking drug appears effective against a wide range of viral infections, including the common cold, flu, stomach viruses, polio and dengue fever -- at least in mice.

The new drug is made from living cell's own defense systems and works by targeting a type of genetic material found only in those cells infected by viruses, MIT researchers explained.

"Currently there are very few antiviral treatments, and most that do exist are highly specific for individual viruses or have undesirable side effects," noted lead researcher Todd Rider, a senior staff scientist at Lincoln Laboratory's Chemical, Biological, and Nanoscale Technologies Group, which is part of MIT.

The new drug is called DRACO (from the more unwieldy "double-stranded RNA activated caspase oligomerizers"). According to Rider, it "has the potential to safely treat or prevent a broad spectrum of viral infections."

Still, a long road awaits before humans might benefit, if ever. Clinical trials remain years away and any drug available to patients might not materialize for a decade, Rider said.

The report was published recently in the online journal PLoS One.

As the researchers explain, DRACO targets a kind of genetic material known as RNA.

When any virus infects a cell it starts making more copies of itself. During this process, viruses produce strings of double-stranded RNA (dsRNA). These strings are not normally found in healthy human or animal cells, the researchers noted.

As part of their natural defense against infection, cells also make proteins that attach to dsRNA -- helping to prevent the virus from replicating. Many viruses escape harm by blocking this cellular defense strategy, however.

DRACO includes a so-called "delivery tag," that allows it to cross cellular membranes and enter any human or animal cell that contains viral dsRNA.

Rider's idea was to combine a dsRNA protein that attaches to cells with another protein that causes cells to die. That means that when DRACO hooks up with the suspect dsRNA, it kickstarts a process whereby the infected cells begin to kill themselves.

On the other hand, if the RNA the drug has targeted is not in the cell (ie, a healthy, uninfected cell) then DRACO leaves that cell alone, Rider explained.

To see if this approach would work, the MIT team tested out the drug on both human and animal cells made in the lab. In addition, they tested their concept in mice infected with influenza. Mice treated with DRACO were cured of the flu, without any adverse effects, Rider said.

"So far, we have not found any side effects in cells or in mice," Rider said. "The mice appeared normal all the time they were alive, and their organs appeared normal when they were examined subsequently," he said.

In addition, he said that they also demonstrated that DRACO is nontoxic in 11 different cell types representing different species including humans, monkeys and mice, and in organ types such as the heart, lung, liver and kidney.

Rider believes that DRACO has the potential to "revolutionize" the treatment and prevention of virtually all viral diseases, including everything from the common cold to Ebola. "Because the antiviral activity of DRACO is so broad-spectrum, we hope that it will even be useful against outbreaks of previously unknown viruses, such as the 2003 SARS outbreak."

"We are currently testing additional viruses in mice and beginning to get promising results with those, too," he added.

Still, don't look for DRACO in your medicine cabinet anytime soon.

"We are hoping to license this technology to a pharmaceutical company that can carry it through larger animal trials and human clinical trials. Realistically, it will probably be at least a decade before you can buy DRACO at the drug store." Rider said.

Mario Stevenson, a professor of medicine and chief of the division of infectious diseases at the University of Miami Miller School of Medicine agreed that the approach is innovative. "But there is a big difference in administering a protein to mice and doing the same protein in humans," he said. "We have learned the hard way that in going from mice to men there are many hurdles to overcome."

In addition, making these proteins is very expensive. That could make any drug out of reach for use in developing countries, where many deadly viruses -- such as dengue fever and Ebola -- are endemic and for which there are no current treatments, Stevenson said.

Stevenson is also concerned that there may be adverse affects in human not yet anticipated or seen in mice or even in human cells. "This happens with a lot of proteins introduced into the circulation," he said.

However, if all the problems can be overcome, then "it could be incredibility important," he added.

More information

For more information on viruses, visit the U.S. National Library of Medicine.

SOURCES: Todd Rider, Ph.D., senior staff scientist, Lincoln Laboratory, Chemical, Biological, and Nanoscale Technologies Group, MIT, Boston; Mario Stevenson, Ph.D., professor, medicine, and chief, division of infectious diseases, University of Miami Miller School of Medicine; July 27, 2011, PLoS One, online


'/>"/>
Copyright©2010 ScoutNews,LLC.
All rights reserved  

Related medicine news :

1. Study Pits New Blood Thinner Against Warfarin For Irregular Heartbeat
2. Small amount of exercise could protect against memory loss in elderly, CU study suggests
3. A new line of defense against sexual assault
4. Penn study finds more effective approach against Achilles heel of ovarian cancer
5. Experimental Drug Promising Against Tough-to-Treat Asthma
6. Grapes protect against ultraviolet radiation
7. Breast-feeding for 6 Months or More Protects Against Asthma
8. Report finds large state disparities in progress against colorectal cancer
9. Breast-Feeding May Not Protect Moms Against MS Relapse
10. Satisfaction with the components of everyday life appears protective against heart disease
11. Kentucky Goes on the Offensive Against Colorectal Cancer
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
'Superdrug' Against Range of Viruses Shows Promise in Animal Trials
(Date:2/5/2016)... ... February 05, 2016 , ... Successful recruitment ... new clinical and scientific initiatives have all marked the last 12 months at ... and CEO of the nation’s oldest cancer center, Candace S. Johnson, PhD, outlined ...
(Date:2/5/2016)... York, New York (PRWEB) , ... February 05, 2016 , ... ... life? The answer may be at the tips of your toes. Foot massage, whether ... as well as pure comfort and relaxation. The American Board of Multiple Specialties ...
(Date:2/5/2016)... ... February 05, 2016 , ... US Sports Camps ... in Dover, NH to direct high-performance kids yoga training. ChildLight Yoga Studio is centrally ... one hour from Boston. , ChildLight Yoga Studio founder Lisa Flynn expresses her excitement, ...
(Date:2/5/2016)... ... February 05, 2016 , ... Give To Cure ... search for and donate to Give To Cure’s campaign that is crowdfunding clinical trials ... users make and share payments through a smart device. In 2015 alone, Venmo processed ...
(Date:2/5/2016)... (PRWEB) , ... February 05, 2016 , ... Dr. Justin ... announce their 2nd Annual No Cost Dental Day to individuals in need. The event ... purpose of this No Cost Dental Day is to provide dental care to community ...
Breaking Medicine News(10 mins):
(Date:2/4/2016)... , Feb. 4, 2016  SciClone Pharmaceuticals, Inc. ... it has entered into a settlement agreement with ... fully resolving the SEC,s investigation into possible violations ... the terms of the settlement agreement, SciClone has ... including disgorgement, pre-judgment interest and a penalty.  This ...
(Date:2/4/2016)... Feb. 4, 2016 Global Immunology Market ... to drive long-term market growth Summary ... of chronic disorders that affect 5–7% of western ... of their symptoms and key patient demographics, they ... immune pathways and an inappropriate immune response. Generally, ...
(Date:2/4/2016)... DIEGO, Feb. 4, 2016  Aethlon Medical, Inc. ... affinity biofiltration devices to treat life-threatening diseases, today ... 2016 ended December 31, 2015. ... objectives set forth in our last quarterly call, ... reinforce our long-term objective to establish the Aethlon ...
Breaking Medicine Technology: